Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors

RODRIGO DOS SANTOS HORTA1*, ANTONIO GIULIANO2*, GLEIDICE EUNICE LAVALLE3*, MARIANA DE PÁDUA COSTA3*, ROBERTO BARACAT DE ARAÚJO3, FERNANDO CONSTANTINO-CASAS2* and JANE MARGARET DOBSON2*

1Department of Veterinary Medicine, Universidade Vila Velha (UVV), Vila Velha, ES 29120-920, Brazil; 2Department of Veterinary Medicine, The Queen's Veterinary School Hospital, University of Cambridge, Cambridge CB3 0ES, UK; 3Department of Veterinary Clinic and Surgery, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG 31270-901, Brazil

Received April 6, 2017; Accepted September 1, 2017

DOI: 10.3892/ol.2017.7323

Abstract. The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non-responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.

Introduction

Mast cell tumour (MCT) is the most common cutaneous malignancy in dogs (1). In view of the wide variation in its biological behaviour, many prognostic factors have been proposed and evaluated in an attempt to improve decision making in the management of this neoplasm (2-4). Among the therapeutic approaches, surgery stands out as the optimal treatment offering the highest rate of cure for most low to intermediate grade MCTs (1,3,5). However, for high grade or biologically aggressive tumours, surgical benefit is limited and metastasis may occur in up to 90% of cases (2,3). Numerous drugs, including glucocorticoids, chemotherapeutic agents and tyrosine kinase inhibitors (TKIs) have been used for treatment of non-resectable MCTs, but the prognosis for such tumours remains guarded to poor (1,3,4). Tyrosine kinases (TKs) are enzymes located on the cell surface, cytoplasm or nucleus, that catalyze the transfer of phosphate groups from adenosine triphosphate molecules (ATP), leading to cellular signaling transmission. In cancer cells, several abnormalities may be found in specific protein kinases, which allows transduction of intracellular signals that ultimately will cause changes in gene transcription, increase cell proliferation, invasion and survival (6,7). Genetic and epigenetic changes can result in alteration on oncopgenes or tumour suppressor genes expression leading to constitutively activated TKs , or abnormal TKs interactions (7-9).

Several molecular abnormalities have been identified and characterized in Veterinary Medicine, particularly in canine MCTs (10). Gain of function mutations involving the KIT receptor and its pathway are considered relevant for the prognosis and treatment of MCT (11-14). Dysregulation of several TKs have been found in different human cancers. Monoclonal antibodies like trastuzumab and cetuximab that respectively target HER-2 and EGFR TK receptors have been approved for human breast cancer (7,15). Imatinib mesylate is a small molecule TKI with a multi-target action towards KITr, PDGFR and Bcr-Abl protein. Imatinib is a well recognized and effective treatment for human gastro-intestinal stromal tumours and chronic myeloid leukemia (16). In veterinary medicine, imatinib was occasionally used in the treatment of canine MCT (17), and greatest effort was directed to the development of similar TKI for veterinary use (7,10).
Masitinib mesylate and toceranib phosphate, are TKIs licensed for use in dogs with non-resectable Grade II or III MCTS in Europe and the United States. They both act intracellularly in the protein kinases KITR and PDGFR α/β, where masitinib also operates in Lyn, Fyn and Lck (18), and toceranib in VGFR and Flt-3 (19). The action against multiple therapeutic targets, allows these molecules to interfere more effectively in the different pathways responsible for cancer progression (7). However, despite the development of such drugs and their increasing use in clinical practice, there is still a lack of established factors that can predict the response to treatment of canine MCTs to TKIs (4,10).

The objective of this study was to evaluate measurable responses of canine MCT to TKIs, correlating this with clinical, histopathological, immunohistochemical and genetic prognostic factors.

Materials and methods

Subject selection and treatment. This study included subjects retrospectively collected from the Queen's Veterinary School Hospital (QVSH) at the University of Cambridge (Cambridge, UK) (n=10), and prospectively enrolled from the Veterinary Hospital of the Universidade Federal de Minas Gerais (UFMG, Belo Horizonte, MG, Brazil)(n=14). The dogs were enrolled if presented with macroscopic cutaneous MCT and stage II, III or IV disease, considered to be at high-risk of MCT related death. For classification as a high-risk stage II, only a cytopathological diagnosis of certain metastasis, was accepted (20).

Incisional biopsies of primary tumours were performed and subjected to histological (Patnaik and Kiupel grading systems), immunohistochemical (Ki-67 and KITr) and genetic (c-kit oncogene) assessment. Clinical staging was performed by physical examination, abdominal ultrasound, fine needle aspiration and cytology of regional lymph nodes, satellite or distant skin lesion and suspected visceral lesions. Lymph node metastasis were identified, on fine needle aspirates (FNA).

Screening of mutations in the c-kit oncogene. The polymerase chain reaction (PCR) for amplification of the fragment of interest in the c-kit oncogene, was performed by Progen, in Vetpat Laboratory (Campinas, SP, Brazil), from the DNA extraction in paraffin embedded tumour, by the proteinase K method. The primers used in the bleaching of the reaction were designed with the help of the BLAST software (Basic Local Alignment Search Tool®, NCBI) and manufactured by Invitrogen (São Paulo, SP, Brazil), as c-kit forward: 5′-ATC TGTCTTCCTTTTCTCCCCC-3′ (sense) and c-kit reverse: 5′-TGGGGTTCCTAAAAGTCATTGT-3′ (antisense). The product generated by these pair of primers had 225 bp in the absence of mutations (native c-kit). Reactions were prepared and planned in a GenPro thermocycler (BIOR Technology), with a maintenance at 95°C for five min, then 30 cycles of 94°C for 45 sec for denaturation of DNA strands, 63°C for 45 sec to pairing and annealing of primers and 72°C for one minute.
to extension, to be finally maintained at 72°C for ten min for molecular stabilization. The amplified material was separated by electrophoresis at 100V, with free amperage. Canine healthy skin samples and milique water were used as positive and negative controls, respectively.

Assessment of response and toxicity. Tumour response to TKI was based on measurements of the primary tumour and all target lesions (including metastatic lymph nodes) before and two-weeks after starting treatment, as recommended by the Response Evaluation Criteria for Solid Tumours (RECIST, v.1.0) (25). Complete response (CR) was defined as a complete disappearance of the mass(es), partial response (PR) was defined as at least 30% reduction in size, stable disease between 20% reduction and 20% increase in size, progressive disease was defined as an increase in size of the mass of more than 20%. Overall response rate (ORR) was calculated based on the total number of subjects that achieved complete and partial response (CR+PR). The disease-free interval (DFI), for subjects who achieved complete remission and overall survival (OS) for all subjects were calculated from the start of TKI administration. Cytology was used to confirm the diagnosis in case of progressive disease and appearance of new lesions. Side effects related to the use of TKI were recorded according to Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v.1.1) (26).

Statistical analysis. Statistical analysis was performed using GraphPad Prism (v.6.01). A matrix correlation was built through Spearman test for searching association between prognostic factors and overall survival. DFI and OS were estimated through Kaplan-Meier curve and the log-rank test of Cox-Mantel was used to compare the curves, according to prognostic factors. P<0.05 was considered to indicate a statistically significant difference. Significant correlations were considered strong when they occurred in over than 49% of the studied population (r>0.7), moderate, as occurred in 9-49% (0.3<r<0.7), and weak, when they occurred in less than 9% of the population (r<0.3).

Results

A total of 24 dogs were included in this study (Table I). Fourteen cases were enrolled prospectively, from the Veterinary Hospital, UFMG and 10 cases were retrospectively included, identified from medical records of subjects treated at the QVSH, University of Cambridge. Tyrosine kinase inhibitors were used as first line therapy in 11 dogs and as a rescue treatment in 13 dogs. All except one subject received concomitant prednisone (n=13, all from UFMG) or prednisolone (n=10, from QVSH). Sixteen subjects had received previous chemotherapeutic agents including: lomustine (n=9), vinblastine (n=4), lomustine followed by chlorambucil (n=2), lomustine followed by vinblastine (n=1). Toceranib was used instead of masitinib in four subjects.

An objective response was obtained in 12/24 subjects (50%), seven of which had CR (29%) and five PR (21%) as shown in Figs. 1 and 2, respectively. Stable (n=4; 17%) or progressive disease (n=8; 33%) was observed in 12 subjects (50%). One subject developed partial remission with masitinib, as a first line therapy, resulting in the tumour becoming resectable. Surgery was performed and the subject continued masitinib treatment with a DFI of 86 days, and an OS of 288 days (144 days after surgery).

The overall survival time for all subjects in this study was 113 days but DFI and OS for subjects who achieved CR was 140 and 164 days. In a matrix correlation only the initial response to TKIs was associated with OS (P=0.03; r²=0.578). As shown in Fig. 3, subjects who achieved measurable responses during the first weeks of treatment (n=12) reached the median at 146 days, while those who remained with stable or progressive disease (n=12) reached the median at 47 days (P=0.02).

Eleven subjects were treated with TKIs as a first line treatment, but 81.8% (9/11) of these, were treated only after post surgical recurrence of the tumour. The ORR for tumours treated with TKI as first line treatment was 54.5% (6/11). Thirteen dogs received TKIs as a second line treatment and 69.2% (9/13) of these had previous surgery as well. The OR for tumours treated with TKI as a second line treatment was 46.2% (6/13). The difference in ORR between the two groups of subjects treated with TKIs as a first or second line treatment was not statistically significant. There was also no significant difference in DFI and OS for the same two groups of subjects, however a tendency for significance in OS was found between the first line treatment compared to the second line treatment group (160 and 103 days, respectively; P=0.2). Similarly, there was no difference in ORR between subjects treated on the first presentation of MCT or after post surgical recurrence of the tumour, however a tendency for significance in OS was found between non-recurrent and recurrent MCTs (123 and 66 days, respectively; P=0.09).

Clinical staging was also not statistically related to prognosis, and subjects in stage II (n=6) and III (n=17), reached a median OS of 130 and 123 days, respectively (P=0.8). There was also no influence of histological grade, mitotic index (1-60 mitotic figures in 10 high-power fields) and Ki-67 value (5,4-46,0%) in OS of these subjects.

Abnormalities in KIT expression were identified in 17/24 (71%) MCTs, 12 with KIT II-pattern and four with a KIT III-pattern, but there was also no correlation with OS. Nevertheless, objective responses (CR+PR) were obtained in 28% (2/7), 54% (7/13) and 75% (3/4) of subjects whose tumours presented with KIT expression pattern I, II and III, respectively, although the number was not appropriate for a contingency analysis. Duplications in exon 11 of the c-kit gene were identified in 6/24 subjects (24%). Of these, measurable responses were observed in 4/6 (67%). A similar rate of response was found for subjects without any identified mutations, through the elected method (8/18, 44% of response to TKI). There was also no difference in OS, according to the mutational status in the exon 11 of the c-kit oncogene.

Positive correlations were found between mitotic index and both grading systems (P=0.009; r²=0.523 for Patnaik grading system; P=0.001; r²=0.617 for Kiupel grading system), KITr pattern and Patnaik grading system (P=0.00001; r²=0.676) and both grading systems (P=0.0006; r²=0.650). Ki67 was not correlated with MI or Patnaik and Kiupel grade.

Side effects were relatively common and are reported in Table II. One dog developed severe illness after...
Table I. Clinical, histopathological, immunohistochemical and genetic features of 24 dogs submitted to treatment with tyrosine-kinase inhibitors for treatment of measurable disease.

| N   | Breed         | Age (months) | Staging | Grade (Patnaik/Kiupel) | Mitotic index | Ki-67 (%) | KITr     | Previous treatment | Clinical response | Follow-up interval | Disease-free survival |
|-----|---------------|--------------|---------|------------------------|---------------|-----------|----------|-------------------|-------------------|-------------------|---------------------|
| 01a (M) | Sharpei       | 72           | III     | Grade 2/ high grade    | 6             | 7.0       | KIT I    | Native            | CR                | 40                | 133                 |
| 02a (T) | French Bulldog | 48           | III     | Grade 3/ high grade    | 20            | 33.0      | KIT III  | Native            | CR                | 124               | 131                 |
| 03a (T) | Crossbreed    | 59           | III     | Grade 3/ high grade    | 60            | 28.7      | KIT II   | Native            | PD                | -                 | 30                  |
| 04 (M)  | French Bulldog | 35           | III     | Grade 3/ high grade    | 5             | 19.0      | KIT III  | Native            | PR                | -                 | 103                 |
| 05a (M) | Schnauzer     | 158          | III     | Grade 2/ low grade     | 3             | 26.0      | KIT I    | Native            | PD                | -                 | 49                  |
| 06 (M)  | Crossbreed    | 115          | III     | Grade 2/ low grade     | 2             | 13.0      | KIT I    | Native            | SD                | -                 | 123                 |
| 07a (T) | Cocker spaniel Pinscher | 133     | III     | Grade 3/ high grade    | 2             | 22.0      | KIT III  | Native            | SD                | -                 | 125                 |
| 08a (M) | Pinscher      | 144          | III     | Grade 2/ high grade    | 4             | 13.0      | KIT I ITD | Prednisone        | CR                | 140               | 164                 |
| 09 (M)  | Crossbreed    | 123          | III     | Grade 2/ low grade     | 3             | 29.0      | KIT II ITD | Prednisone        | CR                | 240               | 280                 |
| 10a (M) | Pinscher      | 132          | III     | Grade 3/ high grade    | 4             | 13.0      | KIT II   | Native            | SD                | -                 | 208                 |
| 11a (M) | Crossbreed    | 162          | II      | Grade 3/ high-grade     | 41            | 14.6      | KIT II   | Native            | PD                | -                 | 47                  |
| 12a (T) | Schnauzer     | 156          | IV      | Grade 2/ high grade    | 33            | 34.0      | KIT I    | Native            | PD                | -                 | 15                  |
| 13 (M)  | Schnauzer     | 144          | III     | Grade 2/ low grade     | 1             | 28.0      | KIT I ITD | Prednisone        | PD                | -                 | 12                  |
| 14a (M) | Pinscher      | 120          | III     | Grade 2/ low grade     | 4             | 22.0      | KIT II ITD | Prednisone, lomustine, vimblastine | PD | - | 42 |
| 15 (M)  | Sharpei       | 120          | III     | Grade 3/ high grade    | 44            | 46.0      | KIT II   | Native            | CR                | 400               | 427                 |
Table I. Continued.

| N  | Breed                  | Age (months) | Staging | Grade (Patnaik/Kiupel) | Mitotic index | Ki-67 (%) | KITr  | e-kit oncogene exon 11 mutational status | Previous treatment | Clinical response | Follow-up | Disease-free interval | Overall survival |
|----|------------------------|--------------|---------|------------------------|---------------|-----------|-------|-----------------------------------|-------------------|-------------------|-----------|-----------------------|------------------|
| 16 | Jack Russel Terrier    | 140          | III     | Grade 3/ high grade    | 15            | 9.0       | KIT II | ITD                               | Prednisolone      | PR                | -         | 57                    |                  |
| 17 | Labrador               | 48           | II      | Grade 2/ low grade      | 2             | 6.3       | KIT II | Native                           | Prednisolone      | SD                | -         | 161                   |                  |
| 18 | Boxer                  | 60           | II      | Grade 2/ high grade     | 2             | 15.3      | KIT II | Native                           | Prednisolone      | PR                | -         | 101                   |                  |
| 19 | Labrador               | 117          | II      | Grade 2/ low grade      | 2             | 6.0       | KIT II | Native                           | Prednisolone      | PR                | -         | 66                    |                  |
| 20 | Dogue de Bordeaux      | 29           | II      | Grade 3/ high grade     | 28            | 37.8      | KIT III | ITD                              | Prednisolone      | CR                | 114       | 203                   |                  |
| 21 | Greyhound              | 132          | II      | Grade 3/ high grade     | 4             | 9.3       | KIT II | Native                           | Prednisolone      | CR                | 52        | 160                   |                  |
| 22 | Border Collie Poodle   | 145          | III     | Grade 2/ low grade       | 5             | 12.4      | KIT I  | Native                           | Prednisolone      | PD                | -         | 47                    |                  |
| 23 | Poodle                 | 36           | III     | Grade 2/ high grade     | 14            | 5.4       | KIT II | Native                           | Prednisolone, vimblastine | PD              | -         | 23                    |                  |
| 24 | Labrador               | 105          | III     | Grade 3/ high grade     | 12            | 6.8       | KIT II | Native                           | -                 | PR                | -         | 288                   | 86               |

*Recurrent tumour. ITD, internal tandem duplication; M, mastinib; T, toceranib; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
main hypotheses might explain this difference: Firstly, our study included a high number of subjects with post surgical recurrent MCTs (18/24) which showed reduced survival rates compared to non recurrent MCT, although this was not statistically significant. A poor outcome is historically reported for recurrent MCTs with related death rates reaching 86-100% of cases as reported by Patnaik et al (21). Secondly, TKIs were administered after failure of chemotherapy in over half of these subjects. As shown by Hahn et al (28), better responses were obtained when mastinib mesylate was used as a first line treatment. However, in our study, no differences were seen in OS in subjects treated as a first or second line treatment with TKIs. A third and most likely hypothesis is that the concomitant use of glucocorticoids might have impaired a favourable and prolonged response to TKIs. The mechanisms involved in tumour resistance to TKIs are still largely unknown, but appear to involve abnormalities in genes responsible for the synthesis of other areas of the targeted proteins, or development of alternative cellular pathways (29). Another mechanism of resistance is the overexpression of ABC transporters (30). Imatinib and dasatinib are TKIs similar to mastinib in its mechanism of action and they are substrates of the ABC transporters, such as P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2), both induced by the administration of glucocorticoids (30). Masitinib is also a P-gp substrate and P-gp overexpression can increase the resistance to mastinib (31). However, multitarget TKIs similar to toceranib, as sunitinib, have been found to inhibit the ABC (32,33). The authors and collaborators found a significant increase in survival in subjects treated with mastinib alone compared to subjects treated with mastinib in combination with prednisolone (data still not published). The efficacy of mastinib could be reduced by the development of a rapid drug resistance caused by the induction of P-gp, from previous or concurrent prednisolone treatment, while toceranib could or could not be affected. In our study only four subjects were treated with toceranib and prednisolone, too few to allow any conclusion. Further studies are needed to evaluate the benefit of adding corticosteroids to mastinib or toceranib.

In this study, one subject received adjuvant therapy with mastinib, once this TKI resulted in partial response of its previous unresectable disease, making it resectable. This subject reached an OS of 288 days from the beginning of mastinib treatment, superior to the median survival of 113 days obtained in this study. This observation could suggest that TKIs responses in the treatment of gross disease may also be useful in the adjuvant scenario. In the presence of minimal residual disease, a reduced development of tumour resistance and even a synergism with other therapeutic approaches could be hypothesized. New clinical trials are required to evaluate the response of canine MCT to these drugs in the adjuvant setting.

In this case series, including dogs with advanced staged disease, the initial response to TKIs was the most significant prognostic factor, as previously reported by Smrkovski et al (27) and Grant et al (34). In contrast, histological grade, mitotic index, Ki-67 value, KITr pattern and even the mutational status in exon 11 of the c-kit oncogene had no impact on OS for these subjects. Increased

Table II. Adverse side effects observed in 24 dogs with advanced staged mast cell tumours treated with tyrosine kinase inhibitors (23 were also treated with glucocorticoids).

| Adverse side effect | Grade | Frequency (%) |
|---------------------|-------|---------------|
| Anaemia             | Grade 2 | 1/24 (4.2) |
|                     | Grade 4 | 1/24 (4.2) |
| Thrombocytopenia    | Grade 4 | 1/24 (4.2) |
| Neutropenia         | Grade 1 | 16/24 (66.7) |
| ALT increase        | Grade 1 | 12/24 (50) |
| ALT increase        | Grade 2 | 2/24 (8.3) |
| Azotemia            | Grade 2 | 1/24 (4.2) |
| Proteinuria         | Grade 1 | 1/24 (4.2) |
| (increase urine      | Grade 3 | 1/24 (4.2) |
| protein/creatinine  | Grade 4 | 1/24 (4.2) |
| Hypoalbuminaemia    | Grade 4 | 1/24 (4.2) |

ALP, alkaline phosphatase; ALT, alanine transferase.

Discussion

In this study, as previously reported by Smrkovski et al (27), a 50% ORR was observed in dogs with unresectable MCTs, treated with TKIs.

The OS of dogs in this study was lower in comparison to reports of Smrkovski et al (27) and Hahn et al (28). Three days of mastinib. The subject presented with a grade 4 non-regenerative anaemia with concomitant thrombocytopenia, grade 2 azotemia and grade 4 proteinuria resulting in hypoalbuminemia/ascites (nephrotic syndrome). The dog was treated with total blood transfusion and fluidtherapy and the drug was suspended, but despite the subject's recovery, tumour recurrence was noted 28 days later and the dog was euthanized.

Figure 1. French Bulldog presenting with (A) a mast cell tumour metastasis on cervical superficial lymph node, (B) but with complete remission after 12 days of treatment with mastinib mesylate.
response rate was found in subjects with II and III KITr staining patterns and in the presence of ITD in the exon 11 of c-kit oncogene, however due to the low number in each subcategory the statistical significance could not be evaluated. The prognostic value of KITr immunelabelling pattern has been evaluated in some studies and although Kiupel et al (2004) showed that the KITr immunelabelling pattern could be a prognostic factor for canine MCT (23), this was not confirmed in more recent studies (35,36). The relevance of c-kit mutational status, as a predictor for TKI response was suggested in older studies (17,19,28). We found an increase response rate in samples arboring c-kit mutations compared with samples with absent mutations, however the number of cases was too small to draw any significant conclusion.

The main limitations of this study were the relatively low number of samples and the heterogenicity of the subjects and type of treatment used, however this is often a common problem in studies of canine MCTs. Genetic assessment of exon 11 was performed using PCR analysis rather than genetic sequencing, so point mutations in the exon 11, could not be assessed. Primers applied in this study were limited only to the exon 11, but whereas there might be c-kit activating mutations in other loci, like exons 2, 5, 6, 7, 8, 9 and 15, (14), these are not proven, at the current state of our knowledge, to be of prognostic or predictive significance.

Although the number of cases in this study was small, there was no correlation between mitotic index and Ki-67 value, which differs from the study conducted by Berlato et al (37). However a moderate correlation was found between mitotic index and both grading systems, Patnaik's grading system and KITr pattern. As expected and previously demonstrated by Giantin et al (35), both grading systems were also moderately correlated with each other.

Masitinib and toceranib are generally well tolerated in dogs, although mild and self-limiting side effects may occur. However, clinical-pathological abnormalities should always be monitored, once severe side effects may occur, like non regenerative anaemia and moderate to severe proteinuria, as seen in our study and also by Miller et al (38).

In conclusion, TKIs can be effective in the treatment of macroscopic advanced staged canine MCTs. Nevertheless, there is lack of factors that could strongly predict the response to treatment. Similar to other studies, we found that the initial response to treatment is the only reliable prognostic factor for those subjects regardless of theclinical stage, histological grade and mitotic index. Nevertheless, history of recurrent MCTs and previous chemotherapeutic agents may reduce response rate. As found in our preliminary results, concomitant use of glucocorticoids may impair the response to TKIs and possibly induce early TKI resistance resulting in reduced OS. Differenty to other similar papers published before all samples were evaluated for Ki-67 value, immunohistochemical pattern of KITr and even the mutational status in exon 11 of the c-kit oncogene. Ki67, KITr immunostaining and c-kit mutation did not give any further relevant informations regarding prognosis and or in the prediction of response to TKIs in the cohort of high-risk MCTs examined, although expression of KIT II and III might result in higher response rate.

Acknowledgements

This study was supported by the National Council for Scientific and Technological Development (CNPq) and Coordination for the Improvement of Higher Education Personnel (CAPES).
References

1. Dobson JM and Scase TJ: Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J Small Anim Pract 48: 424-431, 2007.

2. Welle MM, Bley CR, Howard J and Rüfenacht S: Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 19: 321-339, 2008.

3. London CA and Thamm DH: Mast cell tumors. In: Small Animal Clinical Oncology. Withrow SJ, Vail DM and Page RL (eds). 5th edition. WB Saunders Co, Philadelphia, PA, pp355-355, 2013.

4. Walland J, Brissioli V, Owen L and Dobson J: Canine mast cell tumours: Decision-making and treatment. In Pract 37: 315-332, 2015.

5. Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA and Patnaik AK: Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 224: 236-240, 2004.

6. Amora A and Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979, 2005.

7. London CA: Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 24: 106-112, 2009.

8. Weinstein JB and Joe A: Oncogene addiction. Cancer Res 68: 3077-3080, 2008.

9. Silva RLA: Oncogenes e genes supressores de tumor. In: Oncologia molecular. Ferreira CG and Rocha JCC (eds). 2nd edition. Atheneu, São Paulo, SP, pp43-59, 2010.

10. Rees M: mast cell kinase inhibitors in veterinary oncology. Vet J 205: 122-2, 2013.

11. Zemke D, Yamini B and Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 39: 529-535, 2002.

12. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH and Kiupel M: The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 8: 104-111, 2006.

13. Avery AC: Molecular diagnostics of hematologic malignancies in small animals. J Vet Clin North Am Small Anim Pract 42: 97-110, 2012.

14. Takeuchi Y, Fujino Y, Watanabe M, Takahashi M, Nagawa T, Takeuchi A, Bonokbara M, Kobayashi T, Ohno K, Uchida K, et al.: Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study. J Vet Med Sci 65(6): 492-498, 2013.

15. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.

16. Sleijfer S, Wiemar E and Verweij J: Drug Insight: Gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 5: 102-111, 2008.

17. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, et al.: Effect of tyrosine kinase inhibition by imatinibmesylate on mast cell tumours in dogs. J Vet Intern Med 22: 985-988, 2008.

18. London CA, Malpas PB, Wood-Follis SL, Boucher JR, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, et al.: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11248), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumour following surgical excision. Clin Cancer Res 15: 3856-3865, 2009.

19. Ogilvie GK, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, et al.: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22: 1301-1309, 2008.

20. Antonescu CR, Besmer P, Guo T, Arkad D, Hom G, Koszutyński B, Leever SA, Jeffrey PD, Desantis D, Singer S, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190, 2005.

21. Dolše M, Scharenberg C, Shukla S, Robey RW, Volkman T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A and Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38: 1371-1380, 2010.

22. Mealey KL and Fidel J: P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med 29: 1-6, 2015.

23. Shukla S, Robey RW, Bates SE and Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCBI) and ABCG2. Drug Metab Dispos 37: 359-365, 2009.

24. Hoffmann K, Franz C, Xiao Z, Mohr E, Serba S, Büchler MW and Schwemer P: Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. Anticancer Res 30: 4503-4508, 2010.

25. Grant J, North S and Lanore D: Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours. J Small Anim Pract 57: 283-290, 2016.

26. Giantin M, Granato A, Baratto C, Marconato L, Vascellari M, Morello EM, Vercelli E, Ceccarelli MA, Global gene expression analysis of canine cutaneous mast cell tumor: Could molecular profiling be useful for subtype classification and prognostication? PLoS One 9: e95481, 2014.

27. Costa Casagrande TA, de Oliveira Barros LRM, Fukumatsu H, Cogliati B, Chaible LM, Dagli ML and Matera JM: The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours. Vet Comp Oncol 13: 1-10, 2015.

28. Berlato D, Murphy S, Monti P, Stewart J, Newton JR, Finlad A and Maglennon GA: Comparison of mitotic index and Ki67 index in the prognostication of canine cutaneous mast cell tumours. Vet Comp Oncol 13: 143-150, 2015.

29. Miller RL, Van Lelyveld S, Warland J, Dobson JM and Foale RD: A retrospective review of treatment and response of high-risk mast cell tumours in dogs. Vet Comp Oncol 14: 361-370, 2016.